Last Updated: November 16, 2026

Drug Sales Trends for GIANVI

« Back to Dashboard


Payment Methods and Pharmacy Types for GIANVI (2010)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $10,457,388
INSIDE ANOTHER STORE $64,638,718
[disabled in preview] $46,102,327
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 163,870
INSIDE ANOTHER STORE 820,053
[disabled in preview] 751,838
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $27,402,675
MEDICARE $2,504,920
[disabled in preview] $86,943,760
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for GIANVI
Drug Units Sold Trends for GIANVI

Gianvi Market Analysis, Sales History, Patent Status, and Revenue Projections

Last updated: September 8, 2026

Gianvi is Teva Pharmaceuticals' branded version of drospirenone 3 mg and ethinyl estradiol 0.02 mg tablets, the same active-ingredient combination marketed as Yaz by Bayer. Gianvi entered the U.S. market as a lower-priced alternative after patent litigation and regulatory review. Its commercial opportunity was concentrated in the U.S. oral contraceptive market and declined rapidly as multiple generic manufacturers entered.

Standalone Gianvi sales are not publicly reported in Teva's financial disclosures. Current revenue attributable to the Gianvi brand is likely negligible. The commercially relevant market is the broader U.S. market for drospirenone/ethinyl estradiol tablets, where pricing, payer coverage, pharmacy substitution and competition from generic manufacturers determine revenue.

What is Gianvi and how large is its market?

Gianvi contains 3 mg of drospirenone and 0.02 mg of ethinyl estradiol in a 28-tablet regimen. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic properties. The product is indicated for pregnancy prevention and, under specified conditions, treatment of moderate acne and premenstrual dysphoric disorder. The product label includes the cardiovascular, thromboembolic and hyperkalemia warnings associated with combined hormonal contraceptives and drospirenone-containing products. [1]

The addressable market has three segments:

Market segment Commercial relevance to Gianvi
U.S. drospirenone/ethinyl estradiol tablets Core market
All combined oral contraceptives Competitive substitute market
Acne and premenstrual dysphoric disorder treatment Secondary demand driver

Gianvi competes with Yaz, generic drospirenone/ethinyl estradiol products, Nikki, Loryna, Vestura and other equivalent or near-equivalent oral contraceptives. Most prescriptions are dispensed through pharmacy benefit plans, which favor generic substitution.

When did Gianvi launch and how did sales develop?

Gianvi received U.S. Food and Drug Administration approval in 2010. Teva positioned it as an authorized alternative to Yaz and entered after litigation involving Bayer's Yaz patent estate. [1, 2]

The commercial trajectory had four phases:

Period Market event Expected impact on Gianvi
2010-2011 Initial launch and limited competition Rapid prescription growth
2012-2014 Additional generic entrants Price and share erosion
2015-2019 Mature generic market Low unit economics
2020 onward Loss of remaining key patent barriers and broad substitution Minimal branded value

Gianvi did not develop the durable pricing power associated with a differentiated new molecular entity. Its active ingredients were already established, and the principal commercial advantage was timing of entry and brand recognition.

Teva does not generally report Gianvi as a separate revenue line. The product's sales would have been included in broader generic or pharmaceutical product categories. As a result, public filings do not provide a defensible standalone annual-sales series for Gianvi. [3]

What is the current FDA and Orange Book status of Gianvi?

Gianvi was approved under a separate new drug application rather than as a conventional ANDA generic product. The reference product for the active-ingredient combination was Yaz, marketed by Bayer.

The FDA Orange Book is relevant for three reasons:

  1. It identifies the approved reference products and applicable patent information.
  2. It records whether listed patents remain relevant to abbreviated applications.
  3. It helps determine whether a Paragraph IV certification could create litigation exposure.

Gianvi's initial regulatory value was tied to its ability to enter the market before or alongside later ANDA products. Once multiple ANDA manufacturers received approval for drospirenone/ethinyl estradiol tablets, the brand's regulatory distinction had little commercial significance.

The FDA label identifies Gianvi as a prescription oral contraceptive containing drospirenone and ethinyl estradiol. [1] Product availability has changed over time, and current pharmacy listings may show generic equivalents rather than the Gianvi brand.

What patents protected Gianvi and Yaz?

The primary patent dispute involved Bayer's U.S. Patent No. 6,787,531, which covered aspects of drospirenone-containing pharmaceutical compositions. The patent was listed in connection with Yaz and became the subject of ANDA litigation involving generic applicants, including Barr Laboratories and Teva-related entities. [2, 4]

The patent estate did not create a long-term barrier to competition because:

  • The patent was challenged through Paragraph IV certifications.
  • Courts addressed validity and infringement issues before final market exclusivity expired.
  • Multiple generic manufacturers entered after the relevant patent barriers fell.
  • Formulation and method-of-use claims were less commercially durable than broad composition claims.

The practical exclusivity timeline was:

Event Approximate timing
Yaz U.S. approval 2006
Key Bayer patent expiration period 2020, including applicable extensions and pediatric adjustments
Gianvi approval and launch 2010
Broad generic competition 2010s
Mature multisource market Late 2010s onward

Exact Orange Book patent status should be assessed by historical edition because listed patents, pediatric exclusivity and product status can change over time. The commercial conclusion remains consistent: Gianvi does not have a meaningful surviving patent moat.

How many competitors challenge Gianvi in the U.S.?

Competition is extensive. Products containing the same active ingredients have been marketed by several manufacturers, including Teva, Mylan or Viatris, Lupin, Glenmark, Amneal, Sandoz and other generic suppliers over time.

The principal competitive factors are:

  • Wholesale acquisition cost
  • Medicaid and commercial formulary placement
  • Pharmacy substitution
  • Manufacturer supply reliability
  • 28-tablet packaging
  • Availability of branded or authorized-generic versions
  • Contracting with wholesalers and pharmacy benefit managers

Generic contraceptive products tend to experience rapid price compression when several approved suppliers are available. A product may retain prescription volume while losing most of its revenue because reimbursement shifts toward the lowest-cost supplier.

What are the sales projections for Gianvi?

A standalone Gianvi brand projection should be separated from the projection for the entire drospirenone/ethinyl estradiol market.

Gianvi brand revenue projection

Year Base-case estimated Gianvi brand revenue Commercial interpretation
2024 $0-$2 million Limited or discontinued branded sales
2025 $0-$1.5 million Residual prescriptions, if available
2026 $0-$1 million Further substitution
2027 $0-$1 million No material recovery expected
2028 $0-$1 million Brand value remains immaterial

These are market-model estimates, not reported Teva guidance. The projection assumes that Gianvi remains commercially subordinate to generic drospirenone/ethinyl estradiol products and does not regain preferred formulary status.

Broader drospirenone/ethinyl estradiol market projection

The broader market should remain commercially active because the product has established use in contraception, acne management and premenstrual dysphoric disorder. Revenue growth is likely to be driven by prescription volume rather than price.

Scenario 2025-2028 unit trend Net-price trend Market revenue outlook
Low case Flat to declining Down 8%-12% annually Declining
Base case 1%-3% annual growth Down 4%-8% annually Flat to moderately declining
High case 3%-5% annual growth Down 2%-5% annually Flat to modestly growing

The base case assumes continued generic substitution, stable demand for combined oral contraceptives and no major safety-driven withdrawal. Under this model, market revenue declines despite stable or slightly higher prescription volume.

What generic launch risks exist for Gianvi?

Generic launch risk is no longer a future event for Gianvi. It is the central reason the brand has limited commercial value.

The main risks are:

  • Continued entry by approved ANDA manufacturers
  • Contracting pressure from pharmacy benefit managers
  • Price reductions by manufacturers seeking volume
  • Product shortages that shift share temporarily among suppliers
  • Brand discontinuation or limited distribution
  • Substitution by newer oral contraceptive products and long-acting reversible contraceptives

Generic manufacturers can compete without duplicating Gianvi's brand investment. FDA-approved equivalents generally receive automatic pharmacy substitution where state law and payer policy permit.

What formulation and method-of-use protections remain?

Gianvi's formulation is not commercially differentiated. The tablet contains the same active ingredients and strengths as Yaz and competing equivalents.

Potentially relevant protection categories historically included:

  • Drospirenone and ethinyl estradiol compositions
  • Specific tablet formulations
  • Packaging and dosing regimens
  • Treatment of acne
  • Treatment of premenstrual dysphoric disorder
  • Contraceptive methods using the combination

These claims may have supported litigation or product differentiation during the early lifecycle. They do not provide a significant current barrier because equivalent products are widely available and the principal patents have expired or lost practical exclusivity.

Which companies are positioned to capture the market?

The market is fragmented among generic suppliers. Teva retains manufacturing, distribution and regulatory capabilities, but those capabilities do not ensure brand-level pricing.

Company type Competitive position
Teva Historical Gianvi sponsor and major generic supplier
Viatris and other large generic companies Scale, payer contracting and broad pharmacy access
Specialty generic manufacturers Lower-cost supply and selective channel participation
Bayer Yaz brand legacy, but limited post-patent pricing power
Digital and reproductive-health platforms Demand generation and prescription access rather than manufacturing

The strongest commercial position belongs to suppliers with reliable inventory, low cost of goods and favorable wholesaler contracts. Patent ownership is no longer the primary competitive advantage.

How does Gianvi compare with Yaz and other contraceptives?

Attribute Gianvi Yaz Generic equivalents Long-acting contraceptives
Active ingredients Drospirenone/EE Drospirenone/EE Drospirenone/EE Different products
Brand premium Low or absent Historically higher Minimal Product-specific
Patent protection Expired or commercially weak Expired or commercially weak No meaningful brand moat Depends on product
Formulary position Usually generic Often nonpreferred Frequently preferred Varies
Revenue outlook Negligible brand revenue Limited brand revenue Volume-driven Potentially stronger pricing

Gianvi's closest competitors are generic equivalents, not newer contraceptive mechanisms. The principal market threat comes from substitution within the same active-ingredient class and from long-acting methods such as intrauterine systems and implants.

What is the investment and licensing outlook for Gianvi?

Gianvi has limited licensing value as a standalone brand. The product lacks:

  • A live composition patent moat
  • A differentiated delivery system
  • A protected manufacturing process with clear market impact
  • A publicly disclosed royalty stream
  • Material standalone revenue disclosure

Potential value may exist in a broader portfolio transaction involving Teva's contraceptive products, manufacturing capacity or generic regulatory dossiers. A transaction based solely on Gianvi would likely be justified by residual cash flow, channel access or supply capability rather than intellectual property.

Key Takeaways

  • Gianvi is Teva's drospirenone/ethinyl estradiol product and a lower-priced alternative to Yaz.
  • The product launched in 2010 and entered a market that quickly developed broad generic competition.
  • Standalone Gianvi sales are not publicly disclosed.
  • Current Gianvi brand revenue is likely negligible, with a modeled 2025 revenue range of $0 to $1.5 million.
  • The broader drospirenone/ethinyl estradiol market is expected to remain prescription-stable but price-deflationary.
  • The principal patent barriers associated with Yaz and Gianvi no longer provide meaningful commercial exclusivity.
  • Future value depends on manufacturing economics, distribution and payer access, not patent protection.

FAQs About Gianvi Sales, Patents and Market Competition

Is Gianvi still sold in the United States?

Gianvi's commercial availability has declined substantially as generic drospirenone/ethinyl estradiol products replaced the brand. Pharmacy availability may vary by wholesaler and payer.

Is Gianvi the same as Yaz?

Gianvi and Yaz contain the same strengths of drospirenone and ethinyl estradiol. They are different branded products but are therapeutically comparable for approved uses.

Does Gianvi have patent protection?

Gianvi does not have a commercially meaningful surviving patent barrier. Historical protection was connected to patents covering drospirenone-containing compositions, formulations and related uses.

What is the generic name for Gianvi?

The generic name is drospirenone and ethinyl estradiol tablets, containing 3 mg of drospirenone and 0.02 mg of ethinyl estradiol.

Can Gianvi regain market share?

A material recovery would require a new commercial strategy, such as preferred payer placement, renewed brand promotion or a supply disruption affecting generic competitors. Without those conditions, generic substitution will continue to limit brand revenue.

References

  1. U.S. Food and Drug Administration. (2010). Gianvi prescribing information: Drospirenone and ethinyl estradiol tablets.
  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  3. Teva Pharmaceutical Industries Ltd. (2010-2024). Annual reports and Form 20-F filings.
  4. Bayer Healthcare Pharmaceuticals, Inc. v. Barr Laboratories, Inc., 575 F.3d 1341 (Fed. Cir. 2009).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.